Navigation Links
Abuse-Deterrent Formulations of Purdue's OxyContin and Endo Pharmaceuticals' Opana ER Have Not Increased PCPs' Comfort When Prescribing These Products for Chronic Pain
Date:7/16/2013

BURLINGTON, Mass., July 16, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that despite the replacement of Purdue Pharma's OxyContin and Endo Pharmaceuticals' Opana ER with abuse-deterrent formulations, surveyed primary care physicians (PCPs) do not feel more comfortable prescribing these products for the treatment of chronic pain. In contrast, the majority of surveyed pain specialists report that they are more comfortable prescribing OxyContin and Opana ER now that the products feature abuse-deterrent properties.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The U.S. Physician & Payer Forum report entitled Chronic Pain: How Will U.S. Payers and Prescribers Shape Market Access for Recently Launched and Emerging Products? also finds that 57 percent and 53 percent of surveyed managed care organization (MCO) directors report that coverage of OxyContin and Opana ER has not changed as a result of the products' reformulation to be abuse-deterrent—suggesting that, in many patients, the cost to reimburse OxyContin and Opana ER may outweigh the advantages of the abuse-deterrent formulations. In cases where a non-abuse-deterrent generic opioid was available, MCO directors are likely to only reimburse an abuse-deterrent product in patients with a history of drug abuse—signaling that emerging abuse-deterrent formulations will still be subject to coverage restrictions.

The report also finds that cost will likewise be an important consideration for prescribing and reimbursement of new chronic pain therapies, most notably for Pfizer's novel anti-NGF therapy tanezumab. Seventy-four percent of surveyed PCPs and 48 percent of surveyed pain specialists who do not expect to prescribe tanezumab cite the high expected cost of the drug for the patient as a reason that they would be unwilling to prescribe the drug. As a biologic therapy, tanezumab is expected to be priced at a considerable premium over traditional oral analgesics.

"Although the responses of surveyed physicians suggest that efficacy and safety/tolerability are the most important factors influencing treatment decisions for chronic pain, these physicians anticipate that patient out-of-pocket costs and reimbursement constraints will directly influence their prescribing of emerging chronic pain therapies," said Decision Resources Principal Business Insights Analyst Natalie Taylor, Ph.D. "Even if an emerging therapy demonstrates significantly greater efficacy than the current standard of care for reducing pain, we find that both surveyed PCPs and pain specialists consistently assign lower anticipated patient shares to emerging therapies if the agents were to be covered by MCOs as non-preferred brands. However, emerging therapies that lower the overall long-term costs of treating chronic pain conditions may potentially secure more favorable reimbursement status from MCOs."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Collegium Announces Results of Chronic Pain Patient Survey - Confirms Significant Unmet Medical Need for a Differentiated, Abuse-Deterrent, Extended-Release Opioid
2. KemPharm Supports Recent FDA Recommendations for Hydrocodone-Containing Compounds and Abuse-Deterrent Opioids
3. Abuse-Deterrent Medication Developer, Pisgah Laboratories, Achieves Top 5 Technologies Ranking
4. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
5. XCHC Releases Worldwide Growth Guidance For Its Cannabinoid Treatment Centers and Formulations Targeting Critical Human Ailments, Company Acts on Own Guidance
6. Biodel Awarded NIH Grant to Develop Concentrated Ultra-Rapid-Acting Insulin Formulations for Use in Artificial Pancreas
7. Par Formulations (Formerly Edict Pharmaceuticals) Receives First ANDA Approval
8. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
9. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
10. Valeant Pharmaceuticals To Announce 2013 Second Quarter Results On August 7, 2013
11. GW Pharmaceuticals to Report Q3 2013 Results and Host Conference Call on 5 August, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... , Sept. 8, 2017 Dealmed Medical ... independent supplier of medical equipment, supplies, drugs, vaccines, and ... has entered into an agreement to acquire Vantage Medical ... based in Holtsville, New York . ... in supplying new and emerging medical practices, will operate ...
(Date:9/7/2017)... Sept. 7, 2017 NuvoAir (formerly called ... announced today a partnership with Novartis Pharma AG to distribute ... position as the leading mobile spirometry platform and Novartis, commitment ... ... ...
(Date:9/6/2017)...   PDI , a leader in infection prevention ... educational session focused on the role of chlorhexidine gluconate ... the 2017 Annual Scientific Meeting of the Association for ... the Phoenix Convention Center in ... will also feature PDI,s Prevantics® Device Swab ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... September 21, 2017 , ... The American ... Health Services for professionals in the addiction treatment industry entitled: Special Investigations ... , Insurance companies and state and federal governments are increasingly scrutinizing the addiction ...
(Date:9/21/2017)... ... 21, 2017 , ... Hair restoration surgery is having a ... the International Society of Hair Restoration Surgery (ISHRS). The worldwide volume ... with 635,189 procedures performed in 2016. , "Like other forms of cosmetic ...
(Date:9/21/2017)... , ... September 21, 2017 , ... Bill Howe Plumbing’s ... its customers, and give back to the community. For over 37 years, they have ... successful companies serving plumbing in San Diego. They were chosen as the ...
(Date:9/21/2017)... ... September 21, 2017 , ... Innovatum ... at the Global GS1 Healthcare Conference 2017 in Chicago, IL on October 17-19, ... ensuring label quality and improving patient safety. , Microscan , a ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... and highly accurate cancer screening tests, has received two prestigious recognitions that acknowledge ... survival rates. , Preora has been named a Top 100 Finalist ...
Breaking Medicine News(10 mins):